Cytophage Technologies Ltd.

CYTO

CA2328211081

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 12:50:55 2024-05-24 pm EDT			5-day change	1st Jan Change
0.48 ^CAD	-5.88%		-5.88%	-31.88%

Apr. 30	Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 30	Cytophage Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cytophage Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023

April 30, 2024 at 03:41 am EDT

Cytophage Technologies Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net income was CAD 0.022008 million compared to net loss of CAD 0.706206 million a year ago.

Latest news about Cytophage Technologies Ltd.

Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Cytophage Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Cytophage Technologies Ltd. Appoints Michael D. Cochrane as Newest Member of Board of Directors	Apr. 16	CI
Cytophage Technologies Ltd. Provides Update on Bacteriophage Human Trial at The Ottawa Hospital	Apr. 02	CI
Cytophage Technologies Ltd. Provides Update on Upcoming Product for Egg Production in Canada	Feb. 12	CI
Cytophage Technologies Inc. completed the acquisition of Cuspis Capital III Ltd. (TSXV:CIII.P) in a reverse merger transaction.	Feb. 01	CI
Cuspis Capital III Ltd. announced that it has received CAD 2.5 million in funding	Dec. 21	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Cytophage Technologies Ltd. announced that it expects to receive CAD 2.5 million in funding	Nov. 05	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
Cytophage Technologies Inc. entered into a letter of intent to acquire Cuspis Capital III Ltd. (TSXV:CIII.P) in a reverse merger transaction.	23-05-31	CI
Cytophage Technologies Inc. announced that it expects to receive $5 million in funding from Cuspis Capital III Ltd.	23-05-31	CI
Cuspis Capital III Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Cuspis Capital III Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-30	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-26	CI
Cuspis Capital III Ltd. has completed an IPO in the amount of CAD 5 million.	22-02-01	CI
Cuspis Capital III Ltd. has filed an IPO in the amount of CAD 5 million.	21-11-23	CI

Chart Cytophage Technologies Ltd.

Duration

Period

More charts

Company Profile

Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.

Sector

Pharmaceuticals

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CYTOPHAGE TECHNOLOGIES LTD.	-31.88%	15.04M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals